Pall Buys Biosensor Company
This acquisition marks Pall’s entry into the market for biosensors. Doug Novarro, corporate director of Public Relations for Pall, told IBO, “ForteBio’s portfolio of analytical solutions is an ideal complement to Pall’s existing microbiological monitoring platforms. The acquisition will position us well to take advantage of opportunities in the more than $1 billion biopharmaceuticals process monitoring market.” ForteBio currently has more than 90 employees, according to him.
Port Washington, NY 12/19/11—Filtration, separation and purification solutions provider Pall has signed a definitive agreement to acquire ForteBio for an undisclosed amount. ForteBio is a developer of label-free protein analysis instruments, including the Octel products based on BioLayer Interferometry technology. “BioPharmaceuticals continues to be the engine of our Life Sciences business and an important long-term growth accelerator. The addition of ForteBio’s platforms into our business reinforces Pall’s commitment to helping customers get their life-changing products to market safely and on time,” stated Pall CEO and President Larry Kingsley. ForteBio will become a subsidiary of Pall. The transaction is expected to close by February 2012.
